BBNX Stockholders Have Rights – If You Lost Money Investing in Beta Bionics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP announced a class action lawsuit against Beta Bionics, Inc. (NASDAQ: BBNX) for allegedly misleading investors about the safety and efficacy of its iLet insulin pump. The company downplayed FDA Form 483 concerns in October 2025, claiming issues were minor, but the FDA's February 2026 warning letter revealed serious malfunctions causing dangerous insulin overdoses. BBNX stock plummeted from $31.99 to $12.89 per share between January and February 2026. Investors who suffered losses during the class period (July 30, 2025 - February 24, 2026) may be eligible to recover damages.